Clinical Trial Detail

NCT ID NCT03505320
Title A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (ILUSTRO)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Astellas Pharma Global Development, Inc.
Indications

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Zolbetuximab

Fluorouracil + Leucovorin + Oxaliplatin + Zolbetuximab

Pembrolizumab + Zolbetuximab

Age Groups: adult senior

Additional content available in CKB BOOST